Recent Advances of Research on CEBPA Mutation in Acute Myeloid Leukemia.
10.7534/j.issn.1009-2137.2015.06.047
- Author:
Wen-Qing YU
1
;
Jing-Nan SUN
1
;
Ye-Hui TAN
1
;
Jiu-Wei CUI
1
;
Wei LI
2
Author Information
1. Center of Oncology, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
2. Center of Oncology, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China. E-mail: jdyylw@163.com.
- Publication Type:Journal Article
- MeSH:
CCAAT-Enhancer-Binding Proteins;
Humans;
Leukemia, Myeloid, Acute;
Mutation;
Prognosis
- From:
Journal of Experimental Hematology
2015;23(6):1791-1795
- CountryChina
- Language:Chinese
-
Abstract:
CCAAT/enhancer binding protein alpha gene (CEBPA) is an important transcription factor in maintenance of differentiation of granulocyte series of hematopoietic system. It plays a key role in regulating cell proliferation and differentiation. CEBPA mutation easily occurs in M1 and M2 type of acute myeloid leukemia, about 5%-14% in adult acute myeloid leukemia and 7.9% in children with acute myeloid leukemia. At present, domestic CEBPA mutation research is far less than abroad. This review focuses on the structual characteristics and detection method of CEBPA, CEBPA clinical features, the effect of CEBPA mutation on the prognosis of patients and the choice of treatment.
